VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

NCT07104383 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the investigational drug VK2735 in adults with type 2 diabetes to see how it affects body weight over 78 weeks.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 1,100 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-06 · est. completion 2027-08

Where 127 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT07104383 ↗

Description as written by the study sponsor.

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Treatments tested

VK2735 Drug

VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

Main thing measured	Percent change in body weight from baseline to Week 78 in body weight
Sponsor	Viking Therapeutics, Inc.
Conditions studied	Weight Loss
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07104383 ↗